LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon

J Am Coll Cardiol. 2024 Feb 13;83(6):665-668. doi: 10.1016/j.jacc.2023.12.002.

Authors

Vijay Nambi¹, Layla A Abushamat²

Affiliations

¹ Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; Section of Cardiology, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA. Electronic address: vnambi@bcm.edu.
² Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Electronic address: https://twitter.com/LaylaAbushamat.

PMID: 38325991
DOI: 10.1016/j.jacc.2023.12.002

No abstract available

Keywords: PCSK9i; atherosclerotic cardiovascular disease; legacy effect; low-density lipoprotein cholesterol.

Publication types

Editorial
Comment

MeSH terms

Anticholesteremic Agents*
Atherosclerosis* / prevention & control
Cardiovascular Diseases* / prevention & control
Cholesterol, LDL
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Proprotein Convertase 9

Substances

Anticholesteremic Agents
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proprotein Convertase 9